JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

Anesth Analg 2008; 106:732-738
© 2008 International Anesthesia Research Society
doi: 10.1213/ane.0b013e318163fc76
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, K. A.
Right arrow Articles by Levy, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, K. A.
Right arrow Articles by Levy, J. H.
Related Collections
Right arrow Cardiovascular
Right arrow Coagulation

CARDIOVASCULAR ANESTHESIOLOGY

Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven®) and Fibrinogen (Haemocomplettan® P)

Kenichi A. Tanaka, MD, MSc*, Taro Taketomi, MD*, Fania Szlam, MMSc*, Andreas Calatzis, MD{dagger}, and Jerrold H. Levy, MD*

From the *Department of Anesthesiology, Division of Cardiothoracic Anesthesia, Emory University School of Medicine, Atlanta, Georgia; and {dagger}Haemostasis and Transfusion Medicine, Munich University Clinic, Munich, Germany.

Address correspondence and reprint requests to Jerrold H. Levy, MD, Professor of Anesthesiology, Department of Anesthesiology, Division of Cardiothoracic Anesthesia, Emory University School of Medicine, 1364 Clifton Rd., NE, Atlanta, GA 30322. Address e-mail to jerrold.levy{at}emoryhealthcare.org.

Abstract

BACKGROUND: Recombinant activated factor VII (rFVIIa) is increasingly used for treating refractory bleeding after cardiac surgery. However, hemostasis also depends on coagulation factors, including fibrinogen, which stabilizes platelet plugs at sites of vascular injury. We compared the hemostatic effects of rFVIIa, fibrinogen, or their combination.

METHODS: Blood samples were obtained from 12 volunteers and from 7 patients after cardiopulmonary bypass (CPB). The in vitro effects of rFVIIa (1.5 µg/mL), fibrinogen (100 mg/dL), and the combination were evaluated under simulated coagulopathy in volunteer plasma using heparin (0.1 U/mL) or tissue plasminogen activator (0.1 µg/mL). Hemostatic interventions were compared using thromboelastometry, which measures clotting time (CT, s), angle of thrombus formation, and maximal clot firmness (MCF, mm). The ThrombinoscopeTM was used to quantitate thrombin generation after addition of fibrinogen and/or rFVIIa.

RESULTS: In heparinized volunteer plasma, rFVIIa shortened CT (1st and 3rd quartiles) from 663 (522–736) to 435 (397–531) s, but it did not affect MCF. Fibrinogen increased MCF from 26.0 (24.4–26.7) to 30.5 (26.3–31.5) mm without affecting CT. The combination of rFVIIa and fibrinogen in heparinized samples was most effective in improving CT to 359 (324–522) s and MCF to 29 (27.8–31.0) mm. In tissue plasminogen activator-treated volunteer plasma, fibrinolysis increased by more than 45% by the addition of rFVIIa. After CPB, both CT and MCF were most improved with coadministration of rFVIIa and fibrinogen. Thrombinoscope evaluation demonstrated that rFVIIa decreased the lag time and increased peak thrombin generation, whereas fibrinogen had no effect.

CONCLUSION: The onset of fibrin formation and thrombin generation were shortened after rFVIIa addition, but fibrin clot strength was only increased after fibrinogen supplementation. In vitro clot formation was most improved by using both rFVIIa and fibrinogen in whole blood after CPB.

In surgical patients after prolonged cardiopulmonary bypass (CPB), hemostatic imbalance often results from consumptive loss of coagulation factors, hemodilution, hypothermia, residual anticoagulation, and fibrinolysis.1–4 Under these circumstances, most procoagulant plasma factors are reduced by 40%–50% from baseline, and platelets are often reduced in number and function. Recombinant factor VII (rFVIIa) is increasingly used for refractory bleeding after CPB5–9 beyond its Food and Drug Administration approved indication for the treatment of hemophilia A in patients with Factor VIII inhibiting antibodies. However, it has been suggested the hemostatic efficacy of rFVIIa is limited in the presence of dilutional hypofibrinogenemia,10 and enhanced with fibrinogen supplementation.11 We hypothesized that coadministration of rFVIIa and fibrinogen would be more effective for improving thrombus formation than either respective agent alone. Thus, we investigated the in vitro coagulation effects of rFVIIa and fibrinogen concentrate using viscoelastic measurements of fibrin formation and fluorogenic measurements of thrombin generation.

METHODS

The study procedures were approved by the Emory University human subject research review board and were performed after receiving written informed consent. Blood was obtained from 12 healthy volunteers and seven patients undergoing combined valve and coronary artery bypass grafting surgery requiring at least 2 h of CPB. The volunteers had no history of aspirin ingestion or use of other medications that might interfere with platelet function over the preceding 2 wk.

Thrombelastometry (ROTEM®)
Platelet-poor plasma (PPP) was obtained by centrifugation of the volunteer blood samples at 3000g for 15 min. Coagulopathy in these samples was simulated in vitro by the addition of heparin (Elkins-Sinn, Inc., Cherry Hill, NJ) or tissue plasminogen activator (tPA) (Alteplase®, Genentech, South San Francisco, CA). The final concentration of heparin and tPA in PPP was 0.1 U/mL and 0.1 µg/mL, respectively. The respective model was used to simulate: (1) residual or rebound heparin effect (0.05–0.1 U/mL) that may be observed after protamine administration, and (2) increased fibrinolysis associated with CPB procedures.1 In the third experiment, blood from the surgical patients was obtained 15 min after protamine administration after CPB. Whole blood samples were collected into glass Vacutainer® tubes (Becton Dickinson and Company, Franklin Lakes, NJ) containing 3.2% citrate (1:9 in volume). Four-channel ROTEM® (Pentapharm, Munich, Germany) was performed for both volunteer plasma samples and whole blood surgery patients studies using 340 µL of PPP or whole blood with kaolin activation and 10 µL of 0.4M CaCl2. PPP or whole blood samples were pretreated with either saline (control) or a hemostatic intervention. The hemostatic intervention consisted of fibrinogen (Hemocomplettan® P, CSL Behring, Marburg, Germany), rFVIIa (NovoSeven®, NovoNordisk, Princeton, NJ), or the combination of both drugs in 10.0 µL of volume. The final concentration of added fibrinogen and rFVIIa in the sample was 100 mg/dL and 1.5 µg/mL, respectively.

The following ROTEM variables were obtained: clotting time (CT; s), angle ([{alpha}]°) of thrombus formation, and maximal clot firmness (MCF; mm) (Fig. 1A). In addition, the percent decrease in clot firmness after MCF was calculated to estimate fibrinolysis (Lysis index; LI %) in tPA-treated plasma using the following formula: LI % = 100 x (MCF – CF30)/MCF, where CF30 is the clot firmness at 30 min after MCF was achieved. Aprotinin (50 kallikrein inhibitory units per milliliter) was added in some samples to neutralize tPA-induced activation of plasmin.


Figure 15
View larger version (26K):
[in this window]
[in a new window]

  		Figure 1. A. Thromboelastography recordings obtained using the ROTEM® device. CT = clotting time [normal 100–240] (s), {alpha} = angle of clot formation [normal 59–75] (°), MCF = maximum clot firmness [normal plasma 21–25, normal whole blood 53–65] (mm), Lysis = the decrease of MCF is used to calculate the lysis index % [normal <5%]. B. Representative output of ThrombinoscopeTM system.

 

Thrombin Generation Assay (ThrombinoscopeTM)
Blood samples were collected from the seven CPB patients and blood counts including platelet were performed using coulter counter (Beckman-Coulter, Fullerton, CA). Next, blood samples were centrifuged at 200g for 10 min to obtain platelet-rich plasma (PRP) and the platelet count was again determined. The supernatant (PRP) was transferred to a clean polypropylene tube and the remaining blood sample was recentrifuged for 20 min at 2000g to obtain PPP. Because platelets become highly concentrated in PRP during the centrifugation, PRP was diluted with PPP until the platelet count of the diluted PRP sample was equal to the platelet count in the original whole blood sample. For example, when PRP contains 400 x 103 platelets per mm3 and whole blood sample contains 200 x 103 platelets per mm3, 0.4 mL of PRP was diluted with 0.4 mL of PPP (approximately zero platelets) to obtain 0.8 mL of diluted PRP with approximately 200 x 103 platelets per mm3 verified by platelet count. Diluted PRP was pretreated with either saline (control) or 1 of 3 interventions: fibrinogen (final concentration, 100 mg/dL), rFVIIa (final concentration, 1.5 µg/mL), or the combination of rFVIIa and fibrinogen. The effects of rFVIIa or fibrinogen on thrombin generation were evaluated in PRP using a thrombin generation assay (ThrombinoscopeTM Synapse, BV, Maastricht, The Netherlands).

The concentration of generated thrombin is estimated from the changes in fluorescence intensity when thrombin cleaves the fluorogenic substrate, Z-Gly-Gly-Arg-AMC (benzyloxycarbonyl-Gly-Gly-Arg- 7-amido-4-methylcoumarin, Bachem Bioscience, King of Prussia, PA) as previously described (Fig. 1B).10 For thrombin generation measurements, 80 µL of PRP followed by 20 µL of an activator (Biodis, Signes, France) was added to microtiter plate wells, the plate was incubated for 2–3 min at 37°C, and then 20 µL of the substrate buffer was added. A thrombin calibrator with known thrombin-like activity was monitored in parallel sample wells to allow for calculation of generated thrombin in nM. The progress of the reaction was continuously monitored for 70 min at 37°C with a fluorescence reader (Fluoroscan Ascent, Thermo Labsystems, Franklin, MA) equipped with a 390 nm excitation filter and a 460 nm emission filter. The lag time and peak level of thrombin generation were obtained from the Thrombinoscope (Fig. 1B).

Statistics
Based on previous studies with thrombelastometry and thrombin generation assay, the sample size of 6 was needed to detect 20% change from the controls in MCF variable and peak thrombin level with a β ≥ 0.8 and an {alpha} < 0.05.11,12 The variables of thromboelastometry (CT, {alpha}°, and MCF), and thrombin generation assay (lag time and peak thrombin level) were compared among different hemostatic interventions against the control (no intervention) using the Kruskal– Wallis H-test, followed by the Mann–Whitney U-test with Bonferroni's correction using the SPSS 15.0 (SPSS Inc., Chicago, IL). Data are expressed as the median (25%–75% quartiles) or % changes. P ≤ 0.05 was considered significant. A value of P < 0.05 was considered significant.

RESULTS

Thrombelastometry
Thromboelastometric results are listed in Table 1 and Figures 2 and 3. In volunteer plasma samples treated with heparin (0.1 U/mL), the addition of rFVIIa significantly decreased the time to onset of clot formation, or CT, and it increased the {alpha}° of clot formation when compared with the control sample (Table 1). The addition of fibrinogen did not affect CT or the {alpha}° of clot formation but it did increase MCF. When both agents were added, all three variables were significantly improved over the control sample.


View this table:
[in this window]
[in a new window]

  		Table 1. ROTEM® Variables

 

Figure 25
View larger version (22K):
[in this window]
[in a new window]

  		Figure 2. Thromboelastography recordings obtained with the ROTEM® device after the addition of rFVIIa and/or fibrinogen in the presence of tissue type plasminogen activator in volunteer plasma. Tissue type plasminogen activator was added to stimulate fibrinolysis. rFVIIa = rFVIIa in a final concentration 1.5 µg/mL, fibrinogen = fibrinogen in a final concentration 100 mg/dL. Clotting time (CT) was shorter after the addition of rFVIIa, but the extent of lysis (% lysis) was increased in contrast to the samples with fibrinogen. The maximum clot firmness (MCF) was only improved after the addition of fibrinogen. Fibrinolysis was observed after the addition of rFVIIa and fibrinogen, and the clot structure was improved after the addition of aprotinin (50 kallikrein inhibitory units; aprotinin inhibits plasmin). Lysis index (LI %) shows the extend of fibrinolysis, which was observed at 30 min after MCF.

 


Figure 35
View larger version (29K):
[in this window]
[in a new window]

  		Figure 3. Thromboelastography recordings from the ROTEM® device in whole blood obtained from patients after cardiopulmonary bypass. The samples contained either rFVIIa and/or fibrinogen. Control = no additive, rFVIIa = addition of rFVIIa at final concentration 1.5 µg/mL, fibrinogen = addition of fibrinogen at final concentration 100 mg/dL. Clotting time (CT) was shorter after the addition of rFVIIa compared with the control samples, but the maximum clot firmness (MCF) was not improved. The addition of fibrinogen resulted in increases in MCF, but CT was not improved. The combination of rFVIIa and fibrinogen resulted in the most improvement on ROTEM®. Fibrinolysis was not observed after tissue plasminogen activator addition due to intraoperative (in vivo) aprotinin treatment (data not shown).

 
The addition of tPA to the volunteer plasma samples induced fibrinolysis and reduced MCF by more than 50% within 30 min (Table 1; Fig. 2). In the presence of rFVIIa, CT was significantly shorter compared with the control samples, but there was no difference in MCF. Further, the forming clot showed accelerated fibrinolysis much earlier with than without FVIIa (Fig. 2). The addition of fibrinogen did not reduce fibrinolysis in contrast to the control sample (Table 1). The combination of rFVIIa and fibrinogen did not change the calculated lysis index, and the acceleration of fibrinolysis was still observed compared with the control sample (Table 1; Fig. 2). The fibrinolytic responses were inhibited with the addition of aprotinin, 50 kallikrein inhibitory units/mL to plasma samples pretreated with tPA (Fig. 2).

The platelet count and fibrinogen level (mean ± sd) from the blood obtained from surgical patients after CPB were 70 ± 45 x 103 mm–3 and 154 ± 51 mg/dL, respectively, (CPB duration, 169 ± 57 min). The thromboelastometry tracings in whole blood samples with in vitro addition of rFVIIa or fibrinogen after CPB are shown in Figure 3. The addition of rFVIIa increased CT but not MCF, whereas the addition of fibrinogen induced increases in the {alpha}° of clot formation and MCF (Table 1). The combination of rFVIIa and fibrinogen resulted in increases in CT, {alpha}°, and MCF compared with control CPB samples also obtained after CPB. Because all the patients received aprotinin during CPB, the addition of tPA did not cause fibrinolysis (data not shown).

Thrombin Generation in PRP After CPB
In PRP obtained from surgical patients after CPB, the addition of rFVIIa, or the combination of rFVIIa and fibrinogen, shortened the lag time of thrombin generation by 60.3% and 63.1%, respectively (Fig. 4). There was a nonsignificant increase in lag time (13.6%, P = 0.1 versus control) when fibrinogen was added to the PRP samples compared with the controls (Fig. 4). Peak thrombin levels were increased by 60.6%, 6.8%, and 83.1% relative to the control when rFVIIa, fibrinogen, or both were added respectively (P < 0.01 versus control for rFVIIa, and rFVIIa plus fibrinogen) (Fig. 4).


Figure 45
View larger version (31K):
[in this window]
[in a new window]

  		Figure 4. Thrombin generation as measured with the Thrombinoscope device after the addition of rFVIIa or fibrinogen in platelet-rich plasma obtained from patients after cardiopulmonary bypass. Control = no additives, rFVIIa = rFVIIa at final concentration 1.5 µg/mL, fibrinogen = fibrinogen at final concentration 100 mg/dL. rFVIIa + Fibrinogen = rFVIIa at final concentration 1.5 µg/mL and fibrinogen at final concentration 100 mg/dL. The addition of rFVIIa facilitated the onset of thrombin generation and slightly increased the peak thrombin generation. The addition of fibrinogen had minimal effect on thrombin generation. Representative tracings from six experiments were shown.

 

DISCUSSION

In this study, we found that FVIIa or fibrinogen differentially affects in vitro thrombus formation in the presence of low concentration heparin (0.1 U/mL), tPA (0.1 µg/mL), or CPB-induced coagulopathy. More rapid thrombus formation was demonstrated by shorter CT and a smaller {alpha}° of thrombus formation assessed with thromboelastometry after rFVIIa addition, whereas fibrinogen improved clot strength (MCF) in heparinized and post-CPB samples. The combination of rFVIIa and fibrinogen had additive effects on CT, thromboelastometry {alpha}°, and MCF (Table 1, Fig. 3) than either agent alone. In the presence of tPA in blood from volunteers, neither rFVIIa nor fibrinogen improved clot stability based on the lysis index (Table 1; Fig. 2). Clot stability, as measured by MCF, was restored only after the addition of the antifibrinolytic drug aprotinin.

Although data from thromboelastometry are more reflective of hemostasis due to low-shear conditions (<0.1 s–1), our findings shed light on hemostatic mechanisms associated with the administration of rFVIIa and fibrinogen. The faster onset of thrombus formation (indicated by lower CT), but the lack of an increase in clot strength (indicated by MCF) or peak thrombin level with the addition of rFVIIa to blood samples from patients after CPB, suggests that its hemostatic effects are due to more rapid initiation of thrombin generation rather than increased clot strength. Rapid thrombin generation may be particularly important to achieve hemostasis in the presence of active bleeding in injured vasculature because key proteases (e.g., FXa and thrombin) have a short half-life (15 s to 1 min),13 and fluid transport mechanisms are slow.14 In high shear conditions, platelets promote arterial hemostasis by forming primary hemostatic plugs and presenting negatively charged phospholipid surfaces to support efficient thrombin generation.15 Lower platelet count and reduced aggregation after CPB16 results in limited phospholipid availability at the injury site, hence slower thrombin generation. The end-point of the thrombin generation assay used in this study is thrombin-mediated cleavage of a synthetic substrate (Z-GGR-AMC), whereas thromboelastometry monitors thrombin-mediated conversion of fibrinogen to fibrin. Nevertheless, the results from thromboelastometry in this study corroborate the fluorogenic measurements of thrombin generation. Our present data demonstrate that rFVIIa, but not fibrinogen, decreases the lag time, indicating an increased rate of thrombin generation in thrombocytopenic post-CPB blood (Fig. 4). The peak thrombin level was improved most by combined rFVIIa and fibrinogen, followed by rFVIIa only (Fig. 4), implications that are important to consider when treating bleeding.

Previous in vitro data suggest that rFVIIa compensates for thrombocytopenia by enhancing both local platelet accumulation,17 and thrombin-mediated fibrin formation.18 However, clot formation is also dependent on fibrinogen for clot strength. Therefore, restoring fibrinogen levels before administering rFVIIa for life-threatening bleeding should be considered because the hemostatic efficacy of rFVIIa ultimately depends on increases on thrombin-mediated clot formation. This is supported by our data, and by other reports that with dilutional hypofibrinogenemia, the effect of rFVIIa may be limited.10 Further, fibrinogen supplementation (250 mg/kg) has been shown to confer hemostatic effects in a porcine model of bleeding after traumatic liver laceration.11

The lack of an apparent antifibrinolytic effect of rFVIIa was unexpected. Prior studies suggest that rFVIIa increases the generation of thrombin-activated fibrinolysis inhibitor (TAFI), making fibrin clot less susceptible to plasmin.19 Other data suggest, although, that TAFI has minimal antifibrinolytic effects in hemophilic plasma containing rFVIIa.20 The activation of TAFI is a late process during blood coagulation because thrombin preferentially binds to fibrinogen and factor XIII before it binds to TAFI unless plasma thrombin concentration reaches a high level (>150 nM).21 Because TAFI cleaves the binding site (on the fibrin surface) of tPA and plasminogen, rather than directly antagonizing plasmin,22 it is plausible that rapid fibrin formation with rFVIIa might paradoxically increase tPA–plasminogen interaction on fibrin surfaces, resulting in the early clot lysis by plasmin. In agreement with our data, Nielsen et al. have shown that thrombus formation and breakdown via tissue factor activation is more rapid than via the intrinsic pathway (celite) activation in the presence of tPA.23 Neutralization of plasminogen activator inhibitor-1 by faster formation of Xa and thrombin may also contribute to a rapid fibrinolysis.24 The concentration of tPA that we used was 0.1 µg/mL (approximately 1.7 nM), which is well below the reported plasma levels (approximately 150 nM) during tPA therapy.25,26 Our results, therefore, suggest that the addition of an antifibrinolytic agent may be necessary in the profibrinolytic condition to achieve maximal clot stabilization.

Although platelet and factor transfusions and surgical hemostasis are therapies for postoperative bleeding, rFVIIa, fibrinogen, or their combinations are increasingly being reported for treating refractory bleeding. However, transfusions are not without risks for adverse events, including an increasing recognition of transfusion related acute lung injury, especially after factor and platelet transfusions.27–29 Our data show that rFVIIa and fibrinogen induce specific changes in thromboelastometry variables (Fig. 4), and thus appropriate therapies can be selected.30–32

In conclusion, we have demonstrated that the combination of rFVIIa and fibrinogen improve the onset and stability of thrombus formation. These data suggest that the treatment of bleeding in surgical patients after CPB with rFVIIa might be optimized by first normalizing fibrinogen levels.

Footnotes

Accepted for publication November 20, 2007.

Supported by the Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia.

Dr. Jerrold H. Levy, Section Editor for Hemostasis and Transfusion Medicine, was recused from all editorial decisions related to this manuscript.

REFERENCES

  1. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680–97[Abstract/Free Full Text]
  2. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JI, Goodnough LT. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76:902–8[Web of Science][Medline]
  3. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55:886–91[Web of Science][Medline]
  4. Chandler W. The effects of cardiopulmonary bypass on fibrin formation and lysis: is a normal fibrinolytic response essential? J Cardiovasc Pharmacol 1996;27:S63–8[Web of Science][Medline]
  5. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, Musa MO, Al Homaidhi A, Al Fagih M, Andreasen RB. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000;11:S121–7[Web of Science][Medline]
  6. Hendriks HGD, Van der Maaten J, De Wolf J, Waterbolk TW, Slooff MJH, Van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analgesia 2001;93: 287–9[Abstract/Free Full Text]
  7. Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003;98:1513–5[Web of Science][Medline]
  8. Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, Mann MJ, Achorn NL, Moskalik WF, Hoopes CW. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 2004;98:1635–9[Abstract/Free Full Text]
  9. Sniecinski RM, Chen EP, Levy JH, Szlam F, Tanaka KA. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. Anesth Analg 2007;104:763–5[Abstract/Free Full Text]
  10. Fenger-Eriksen C, Ingerslev J, Sorensen B. Coagulopathy induced by colloid plasma expanders—search for an efficacious haemostatic intervention. Acta Anaesthesiol Scand 2006;50: 899–900[Web of Science][Medline]
  11. Fries D, Krismer A, Klingler A, Streif W, Klima G, Wenzel V, Haas T, Innerhofer P. Effect of fibrinogen on reversal of dilutional coagulopathy. a porcine model. Brit J Anaesth 2005; 95:172–7[Abstract/Free Full Text]
  12. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4–15[Medline]
  13. Jesty J, Beltrami E. Positive feedbacks of coagulation: their role in threshold regulation. Arteriosclerosis Thromb Vasc Biol 2005; 25:2463–9[Abstract/Free Full Text]
  14. Slack SM, Cui Y, Turitto VT. The effects of flow on blood coagulation and thrombosis. Thromb Haemost 1993;70:129–34[Web of Science][Medline]
  15. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958–65[Web of Science][Medline]
  16. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388–93[Web of Science][Medline]
  17. Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus ECM, Heemskerk JWM, De Groot PG. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005;3:742–51[Web of Science][Medline]
  18. Lisman T, Adelmeijer J, Heijnen HFG, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIb/beta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004;103:1720–7[Abstract/Free Full Text]
  19. Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002;35:616–21[Web of Science][Medline]
  20. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Brit J Haematol 2005;131:645–55[Web of Science][Medline]
  21. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arteriosclerosis Thromb Vascul Biol 2006;26:2445–53
  22. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA. Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 1993;82:2433–41[Abstract/Free Full Text]
  23. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII. J Heart Lung Transplant 2006;25:1247–52[Web of Science][Medline]
  24. Urano T, Nagai N, Matsuura M, Ihara H, Takada Y, Takada A. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998;80:161–6[Web of Science][Medline]
  25. Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz KH, Herrmann KS. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989;64:448–53[Web of Science][Medline]
  26. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998;79:134–9[Web of Science][Medline]
  27. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New Engl J Med 1999;340:409–17[Abstract/Free Full Text]
  28. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, Murkin J, Nadel A. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004;44:1143–8[Web of Science][Medline]
  29. Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB, Huhmayr RD, Gajic O. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007;131:1308–14[Web of Science][Medline]
  30. Nuttall GA, Oliver WC, Santrach PJ, Bryant S, Dearani JA, Schaff HV, Ereth MH. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001;94:773–81[Web of Science][Medline]
  31. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312–9[Abstract/Free Full Text]
  32. Kawaguchi C, Takahashi Y, Hanesaka Y, Yoshioka A. The in vitro analysis of the coagulation mechanism of activated factor VII using thrombelastogram. Thromb Haemost 2002;88:768–72[Web of Science][Medline]



This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
T. Lang, K. Johanning, H. Metzler, S. Piepenbrock, C. Solomon, N. Rahe-Meyer, and K. A. Tanaka
The Effects of Fibrinogen Levels on Thromboelastometric Variables in the Presence of Thrombocytopenia
Anesth. Analg., March 1, 2009; 108(3): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
R. Sniecinski, F. Szlam, E. P. Chen, S. O. Bader, J. H. Levy, and K. A. Tanaka
Antithrombin Deficiency Increases Thrombin Activity After Prolonged Cardiopulmonary Bypass
Anesth. Analg., March 1, 2008; 106(3): 713 - 718.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
F. Szlam, T. Taketomi, C. A. Sheppard, C. L. Kempton, J. H. Levy, and K. A. Tanaka
Antithrombin Affects Hemostatic Response to Recombinant Activated Factor VII in Factor VIII Deficient Plasma
Anesth. Analg., March 1, 2008; 106(3): 719 - 724.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, K. A.
Right arrow Articles by Levy, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, K. A.
Right arrow Articles by Levy, J. H.
Related Collections
Right arrow Cardiovascular
Right arrow Coagulation

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press